Status:
COMPLETED
Impact of Covid-19 in Congenital Heart Disease
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
Pr. Jean-Benoît THAMBO, Bordeaux (président)
Dr. Céline GRUNENWALD GRONIER, Strasbourg
Conditions:
Congenital Heart Disease
Covid-19
Eligibility:
All Genders
Brief Summary
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patient with CHD as defined in the international classification ACC-CHD
- Covid-19 infection over the study period
- Exclusion criteria:
- \- Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT04336384
Start Date
March 1 2020
End Date
December 30 2020
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uh Montpellier
Montpellier, France, 34295